Literature DB >> 28694182

Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Bartlomiej M Getta1, Mikhail Roshal2, Junting Zheng3, Jae H Park4, Eytan M Stein4, Ross Levine5, Esperanza B Papadopoulos6, Ann A Jakubowski6, Nancy A Kernan7, Peter Steinherz8, Richard J O'Reilly7, Miguel-Angel Perales6, Sergio A Giralt6, Martin S Tallman4, Brian C Shaffer9.   

Abstract

Mixed phenotype acute leukemia (MPAL) represents a poorly characterized group of acute leukemias that lack an accepted therapeutic approach and are typically associated with poor outcomes. We present our experience of genomic profiling, pretransplantation therapy, and transplantation outcomes for 36 well-characterized pediatric and adult patients with MPAL, defined according to the 2016 World Health Organization leukemia update. A predominance of acute lymphoid leukemia (ALL)-associated mutations and cytogenetic abnormalities was noted. Remission rates after induction appeared comparable among adults (20 of 23) and children (11 of 13) and among those who received ALL (10 of 11) or acute myeloid leukemia-type (21 of 25) induction. Adults underwent transplantation in first remission while children underwent transplantation in the setting of relapse or MLL rearrangement. The median follow-up among the 25 patients who underwent transplantation was 39.6 months and median overall survival was not reached. Relapse after transplantation was associated with MLL rearrangement (P = .022), reduced-intensity conditioning (P < .001), and higher WBC at diagnosis (P = .034). These data highlight differing therapeutic approaches between adult and pediatric MPAL and demonstrate favorable survival of adult MPAL patients consolidated with allogeneic hematopoietic cell transplantation.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic cell transplantation; Mixed phenotype acute leukemia; Somatic mutations

Mesh:

Year:  2017        PMID: 28694182      PMCID: PMC5682215          DOI: 10.1016/j.bbmt.2017.06.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  45 in total

1.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

Authors:  H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.

Authors:  Hong Tian; Yang Xu; Liming Liu; Lingzhi Yan; Zhengming Jin; Xiaowen Tang; Yue Han; Zhengzheng Fu; Huiying Qiu; Aining Sun; Depei Wu
Journal:  Leuk Res       Date:  2016-04-04       Impact factor: 3.156

3.  Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

Authors:  K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

4.  Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.

Authors:  Qi-Fa Liu; Zhi-Ping Fan; Mei-Qing Wu; Jing Sun; Xiu-Li Wu; Dan Xu; Qian-Li Jiang; Yu Zhang; Fen Huang; Yong-Qiang Wei; Jie Zhao; Guo-Pan Yu; Fan-Yi Meng
Journal:  Ann Hematol       Date:  2012-12-30       Impact factor: 3.673

5.  Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.

Authors:  M Weiss; P Maslak; E Feldman; E Berman; J Bertino; T Gee; L Megherian; K Seiter; D Scheinberg; D Golde
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

6.  Cord-Blood Transplantation in Patients with Minimal Residual Disease.

Authors:  Filippo Milano; Ted Gooley; Brent Wood; Ann Woolfrey; Mary E Flowers; Kristine Doney; Robert Witherspoon; Marco Mielcarek; Joachim H Deeg; Mohamed Sorror; Ann Dahlberg; Brenda M Sandmaier; Rachel Salit; Effie Petersdorf; Frederick R Appelbaum; Colleen Delaney
Journal:  N Engl J Med       Date:  2016-09-08       Impact factor: 91.245

7.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

8.  Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.

Authors:  Donavan T Cheng; Janice Cheng; Talia N Mitchell; Aijazuddin Syed; Ahmet Zehir; Nana Yaa T Mensah; Alifya Oultache; Khedoudja Nafa; Ross L Levine; Maria E Arcila; Michael F Berger; Cyrus V Hedvat
Journal:  J Mol Diagn       Date:  2014-07-10       Impact factor: 5.568

9.  Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia.

Authors:  A Venditti; G Del Poeta; F Buccisano; A Tamburini; M C Cox-Froncillo; G Aronica; A Bruno; B Del Moro; A M Epiceno; A Battaglia; L Forte; M Postorino; V Cordero; S Santinelli; S Amadori
Journal:  Leukemia       Date:  1998-07       Impact factor: 11.528

10.  Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes.

Authors:  Olive S Eckstein; Linghua Wang; Jyotinder N Punia; Steven M Kornblau; Michael Andreeff; David A Wheeler; Margaret A Goodell; Rachel E Rau
Journal:  Exp Hematol       Date:  2016-05-18       Impact factor: 3.084

View more
  3 in total

1.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

2.  Rare Case of Mixed Phenotype Acute Leukemia Presenting as a Myeloid Sarcoma Without Leukemic Involvement.

Authors:  Jeffrey Means; David Feldman; Allison Shaw; Khoan Vu
Journal:  Perm J       Date:  2022-04-05

3.  Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia.

Authors:  Di Wu; Wenlan Chen; Zhichao Chen; Qiubai Li
Journal:  Case Rep Hematol       Date:  2021-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.